Clinical Trials In Washington State
Discover hundreds of clinical trials in Washington State.
Search clinical trials in Washington State by city, condition or phase.
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Sponsor:
Jasper Therapeutics, Inc.
Location:
Code:
NCT04429191
Conditions
MYELODYSPLASTIC SYNDROME; MDS
ACUTE MYELOID LEUKEMIA; AML
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05621291
Conditions
B-All
Acute Lymphoblastic Leukemia
Eligibility Criteria
Sex: All
Age: 1 - 25
Healthy Volunteers: Not accepted
Interventions
NGS testing
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT04873362
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Trastuzumab Emtansine
Placebo
Trastuzumab
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Sponsor:
Academic and Community Cancer Research United
Location:
Code:
NCT04626791
Conditions
Mantle Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Acalabrutinib
Bortezomib
Cyclophosphamide
Cytarabine
Doxorubicin Hydrochloride
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Location:
Code:
NCT04935476
Conditions
COVID-19
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
Dapsone 85 mg PO BID
Placebo 85 mg PO BID
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Sponsor:
Keryx Biopharmaceuticals
Location:
Code:
NCT04523727
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Eligibility Criteria
Sex: All
Age: 6 - 16
Healthy Volunteers: Not accepted
Interventions
ferric citrate
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Sponsor:
RayzeBio, Inc.
Location:
Code:
NCT05477576
Conditions
GEP-NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RYZ101
Everolimus
Sunitinib
Octreotide
Lanreotide